Literature DB >> 24342474

An anonymous unlinked sero-prevalence survey of HIVHCV in an urban Emergency Department.

Debbie Y Mohammed1, Eugene Martin2, Charlotte Sadashige3, Michael Jaker4, Sindy Paul3.   

Abstract

BACKGROUND: In 2002, the sero-prevalence of human immunodeficiency virus-1 (HIV) in the Emergency Department (ED), University Hospital, Newark, New Jersey was 10.4%. Both HIV and hepatitis C virus (HCV) are transmitted by injection drug use (IDU) or sexual contact. However, the degree of concurrent positive HCV antibody status in HIV-infected ED patients is unknown.
OBJECTIVES: In this study we determined the sero-prevalence of HIV and HIVHCV in HIV-positive patients in the ED. STUDY
DESIGN: A cross-sectional study using an anonymous sero-prevalence survey was conducted from 7/1/2008 to 8/23/2008. Medical records were reviewed and de-identified; remnant blood specimens were also de-identified and tested for HIV antibody, and if positive, HCV antibody.
RESULTS: Of 3488 specimens, 225 (6.5%, 95% CI: 5.7-7.3%) were positive for HIV antibody. Seventy-four patients 74/225 (32.9%, 95% CI: 33.8-46.5%) were unaware of their sero-positivity. Forty percent of HIV positive patients (90/225, 95% CI: 33.8-46.5%) were HCV antibody positive. The highest seroprevalence of HIVHCV antibody was among older patients (≥ 45 years), and patients with positive urine toxicology and elevated liver function tests. DISCUSSION: Given the high prevalence of HIV and HIVHCV antibody in the ED, routine testing is important for patients ≥ 45 years with positive urine toxicology and elevated liver function tests.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  AIDS; ALT; AST; AUS; Anonymous unlinked sero-survey; CI; Confidence Interval; ED; ELISA; Emergency Department; Emergency department; Enzyme-Linked Immuno-Sorbent Assay; HCV; HIV; HIVHCV; IDU; LFT; NIDU; NJ; New Jersey; Prevalence HIVHCV antibody; acquired immunodeficiency syndrome; alanine aminotransferase; anonymous unlinked sero-survey; aspartate aminotransferase; hepatitis C virus; human immunodeficiency virus-1; human immunodeficiency virus–hepatitis C virus; injection drug use; liver function tests; non-IDU

Mesh:

Substances:

Year:  2013        PMID: 24342474     DOI: 10.1016/j.jcv.2013.08.025

Source DB:  PubMed          Journal:  J Clin Virol        ISSN: 1386-6532            Impact factor:   3.168


  2 in total

1.  Parallel declines in HIV and hepatitis C virus prevalence, but not in herpes simplex virus type 2 infection: A 10-year, serial cross-sectional study in an inner-city emergency department.

Authors:  Eshan U Patel; Oliver Laeyendecker; Yu-Hsiang Hsieh; Richard E Rothman; Gabor D Kelen; Thomas C Quinn
Journal:  J Clin Virol       Date:  2016-05-10       Impact factor: 3.168

2.  [Prevalence of blood-borne pathogens among 275 trauma patients : A prospective observational study].

Authors:  S Wicker; H F Rabenau; B Scheller; I Marzi; S Wutzler
Journal:  Unfallchirurg       Date:  2016-08       Impact factor: 1.000

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.